866-997-4948(US-Canada Toll Free)

Mitochondrial Diseases - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Dec 2013

Category :

Metabolic Disorders

No. of Pages : 47 Pages


Global Markets Directs, \'Mitochondrial Diseases Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Mitochondrial Diseases, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mitochondrial Diseases. Mitochondrial Diseases Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Mitochondrial Diseases.
  • A review of the Mitochondrial Diseases products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Mitochondrial Diseases pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Mitochondrial Diseases.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Mitochondrial Diseases pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Mitochondrial Diseases Overview 6
Therapeutics Development 7
Pipeline Products for Mitochondrial Diseases - Overview 7
Pipeline Products for Mitochondrial Diseases - Comparative Analysis 8
Mitochondrial Diseases - Therapeutics under Development by Companies 9
Mitochondrial Diseases - Therapeutics under Investigation by Universities/Institutes 10
Mitochondrial Diseases - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Mitochondrial Diseases - Products under Development by Companies 14
Mitochondrial Diseases - Products under Investigation by Universities/Institutes 15
Mitochondrial Diseases - Companies Involved in Therapeutics Development 16
NeuroVive Pharmaceutical AB 16
ElexoPharm GmbH 17
Sphaera Pharma Pvt. Ltd. 18
Stealth Peptides Inc. 19
Orphan Technologies Ltd 20
Mitochondrial Diseases - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Assessment by Therapeutic Class 30
Drug Profiles 33
OT-15 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
MTP-131 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
NVP-015 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Mitochondrial Dysfunction Program - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Alkylaminoquinone Based Multifunctional Radical Quenchers - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Drug For Mitochondrial Diseases - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Eurostars Program - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Mitochondrial Diseases - Recent Pipeline Updates 41
Mitochondrial Diseases - Discontinued Products 44
Mitochondrial Diseases - Product Development Milestones 45
Featured News & Press Releases 45
Mar 18, 2013: St George’s University Of London Receives £3.3m MRC Grant For Developing New Treatment For Rare Metabolic Disorder 45

Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 47
Disclaimer 47

List of Table


Number of Products under Development for Mitochondrial Diseases, H2 2013 7
Number of Products under Development for Mitochondrial Diseases - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Number of Products under Investigation by Universities/Institutes, H2 2013 10
Comparative Analysis by Clinical Stage Development, H2 2013 11
Comparative Analysis by Early Stage Development, H2 2013 12
Comparative Analysis by Unknown Stage Development, H2 2013 13
Products under Development by Companies, H2 2013 14
Products under Investigation by Universities/Institutes, H2 2013 15
Mitochondrial Diseases - Pipeline by NeuroVive Pharmaceutical AB, H2 2013 16
Mitochondrial Diseases - Pipeline by ElexoPharm GmbH, H2 2013 17
Mitochondrial Diseases - Pipeline by Sphaera Pharma Pvt. Ltd., H2 2013 18
Mitochondrial Diseases - Pipeline by Stealth Peptides Inc., H2 2013 19
Mitochondrial Diseases - Pipeline by Orphan Technologies Ltd, H2 2013 20
Assessment by Monotherapy Products, H2 2013 21
Number of Products by Stage and Target, H2 2013 23
Number of Products by Stage and Mechanism of Action, H2 2013 25
Number of Products by Stage and Route of Administration, H2 2013 27
Number of Products by Stage and Molecule Type, H2 2013 29
Number of Products by Stage and Therapeutic Class, H2 2013 32
Mitochondrial Diseases Therapeutics - Recent Pipeline Updates, H2 2013 41
Mitochondrial Diseases - Discontinued Products, H2 2013 44

List of Chart


Number of Products under Development for Mitochondrial Diseases, H2 2013 7
Number of Products under Development for Mitochondrial Diseases - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Early Stage Products, H2 2013 12
Assessment by Monotherapy Products, H2 2013 21
Number of Products by Top 10 Target, H2 2013 22
Number of Products by Stage and Top 10 Target, H2 2013 23
Number of Products by Top 10 Mechanism of Action, H2 2013 24
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 25
Number of Products by Top 10 Route of Administration, H2 2013 26
Number of Products by Stage and Top 10 Route of Administration, H2 2013 27
Number of Products by Top 10 Molecule Type, H2 2013 28
Number of Products by Stage and Top 10 Molecule Type, H2 2013 29
Number of Products by Top 10 Therapeutic Class, H2 2013 30
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 31

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *